ACM
CNSP icon

Altium Capital Management’s CNS Pharmaceuticals CNSP Stock Holding History

Altium Capital Management’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1
Closed -$951K – 128
2020
Q4 		$951K Buy
+1
New +$1.85M 0.36% 82

Other funds holding CNSP

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Altium Capital Management's CNSP Position: Q1 2021 in Review

Altium Capital Management sold out of CNS Pharmaceuticals (CNSP) in Q1 2021, closing a stake of 1 share — an estimated $951K sold.

Altium Capital Management first reported a position in CNSP in Q4 2020 and held it in 1 quarter. The position peaked at $951K in Q4 2020. 1 fund tracked by Wall St. Rank holds CNSP as of Q1 2021.

  • Altium Capital Management reported no remaining CNS Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Altium Capital Management sold 1 CNS Pharmaceuticals share in Q1 2021, an estimated $951K.
  • Altium Capital Management first reported a position in CNS Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Altium Capital Management's CNS Pharmaceuticals position peaked at $951K in Q4 2020.
  • 1 fund tracked by Wall St. Rank held CNS Pharmaceuticals as of Q1 2021.

Based on Altium Capital Management's 13F filing for Q1 2021, filed 6 May 2021.